DI-037

RISK OF HYPERTENSION IN PATIENTS TREATED WITH MIRABEGRON. STRATEGY FOR PRIORITIZATION OF A DRUG SAFETY WARNING.

Gázquez Pérez R, Jiménez Pichardo L, Sierra Sánchez JF, Rojas Corrales O, García Bonilla A, Alcalá Soto A

UGC-Farmacia. AGS Norte de Cádiz.

BACKGROUND

On September 7th 2015, the European Medicines Agency (EMA) and the Spanish Agency for Medicines and Health Products (AEMPS) notified a drug safety warning (DSW) through a communication to healthcare professionals on the use of mirabegron. It showed new recommendations for its use in relation to the risk of increased blood pressure.

PURPOSE

To detect patients under mirabegron treatment with an increased risk of hypertension. To make a notification to physicians.

MATERIAL AND METHODS



RESULTS



CONCLUSIONS

Five out of ten patients under mirabegron treatment can be considered as risk population for hypertension. The analysis allows prioritization on the diffusion of information identifying patients at risk and main prescribers. Further studies would be necessary to confirm the impact of this intervention.

Bibliography: AstellasPharma, EMA. Comunicación dirigida a profesionales sanitarios: Betmiga (mirabegrón): Nuevas recomendaciones sobre el riesgo del aumento de la presión arterial. 7 Sept 2015. Available at: https://sinaem.agemed.es/CartasFarmacovigilanciaDoc/2015/DHCP-Betmiga-07-septiembre-2015.pdf. Consulted: 8/09/2015.